Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$17.25 +6.3%	$20.41	$13.53 ▼ $35.25	$1.73B	2.35	1.43 million shs	3.15 million shs
KNSA Kiniksa Pharmaceuticals	$26.72 -0.2%	$22.31	$17.38 ▼ $28.56	$1.94B	0.07	480,936 shs	373,453 shs
STOK Stoke Therapeutics	$9.09 +4.9%	$7.96	$5.35 ▼ $17.58	$496.01M	1.2	711,976 shs	721,085 shs
TARS Tarsus Pharmaceuticals	$47.14 -0.4%	$48.26	$20.08 ▼ $57.28	$1.98B	0.94	694,412 shs	687,745 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+1.97%	-18.56%	+6.08%	-41.30%	-27.96%
KNSA Kiniksa Pharmaceuticals	-0.68%	-0.74%	+32.00%	+31.94%	+31.68%
STOK Stoke Therapeutics	-1.03%	-11.27%	+44.09%	-32.03%	-27.47%
TARS Tarsus Pharmaceuticals	+1.88%	-8.84%	-0.35%	-11.25%	+24.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.9773 of 5 stars	4.5	1.0	0.0	2.3	2.5	0.6
KNSA Kiniksa Pharmaceuticals	2.5696 of 5 stars	3.5	1.0	0.0	3.0	3.3	0.6
STOK Stoke Therapeutics	3.454 of 5 stars	3.6	0.0	4.8	2.6	1.7	0.0
TARS Tarsus Pharmaceuticals	2.9741 of 5 stars	4.5	0.0	0.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	182.63% Upside
KNSA Kiniksa Pharmaceuticals	3.00	Buy	$38.80	45.21% Upside
STOK Stoke Therapeutics	3.14	Buy	$25.60	181.78% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.33	40.71% Upside

Current Analyst Ratings Breakdown

Latest STOK, KNSA, TARS, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
5/5/2025	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$46.00 ➝ $51.00
5/2/2025	TARS Tarsus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $84.00
4/29/2025	KNSA Kiniksa Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/16/2025	KNSA Kiniksa Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00
4/9/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/28/2025	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$42.00 ➝ $42.00
3/19/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $47.00

(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	27.31	N/A	N/A	$12.04 per share	1.43
KNSA Kiniksa Pharmaceuticals	$481.17M	4.03	N/A	N/A	$6.23 per share	4.29
STOK Stoke Therapeutics	$36.56M	13.57	N/A	N/A	$3.57 per share	2.54
TARS Tarsus Pharmaceuticals	$233.67M	8.47	N/A	N/A	$5.95 per share	7.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$132.53M	-$4.58	N/A	N/A	N/A	-41.07%	-16.22%	-10.94%	N/A
KNSA Kiniksa Pharmaceuticals	$14.08M	-$0.25	N/A	106.88	N/A	-2.36%	-7.31%	-5.95%	7/22/2025 (Estimated)
STOK Stoke Therapeutics	-$104.70M	-$1.68	N/A	N/A	N/A	-629.90%	-54.45%	-40.77%	N/A
TARS Tarsus Pharmaceuticals	-$135.89M	-$2.73	N/A	N/A	N/A	-103.64%	-55.86%	-39.28%	5/14/2025 (Estimated)

Latest STOK, KNSA, TARS, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.75	N/A	N/A	N/A	$71.19 million	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million
3/24/2025	Q4 2024	STOK Stoke Therapeutics	-$0.56	-$0.18	+$0.38	-$0.18	$4.20 million	$22.61 million
2/25/2025	Q4 2024	BEAM Beam Therapeutics	-$1.25	-$1.09	+$0.16	-$1.09	$16.47 million	$30.00 million
2/25/2025	Q4 2024	KNSA Kiniksa Pharmaceuticals	-$0.06	-$0.12	-$0.06	-$0.12	$123.42 million	$122.50 million
2/25/2025	Q4 2024	TARS Tarsus Pharmaceuticals	-$0.68	-$0.60	+$0.08	-$0.60	$58.80 million	$66.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	5.22%	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	5.69	5.69
KNSA Kiniksa Pharmaceuticals	N/A	3.24	2.95
STOK Stoke Therapeutics	N/A	5.09	5.09
TARS Tarsus Pharmaceuticals	0.30	5.42	5.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
KNSA Kiniksa Pharmaceuticals	53.95%
STOK Stoke Therapeutics	N/A
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	4.20%
KNSA Kiniksa Pharmaceuticals	54.57%
STOK Stoke Therapeutics	11.30%
TARS Tarsus Pharmaceuticals	8.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	79.33 million	Optionable
KNSA Kiniksa Pharmaceuticals	220	72.64 million	32.80 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	46.98 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	35.07 million	Optionable

STOK, KNSA, TARS, and BEAM Headlines

Recent News About These Companies

Tarsus to Participate in Upcoming Investor Conferences

May 8 at 5:00 PM | globenewswire.com

Cutter Capital Management LP Invests $6.23 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 8 at 7:25 AM | marketbeat.com

The Goldman Sachs Group Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $51.00

May 7 at 11:27 AM | marketbeat.com

Voya Investment Management LLC Purchases 18,000 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 7 at 4:18 AM | marketbeat.com

Raymond James Financial Inc. Acquires Shares of 19,999 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 7 at 3:30 AM | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $51.00 at The Goldman Sachs Group

May 7 at 1:23 AM | americanbankingnews.com

Freestone Grove Partners LP Makes New $439,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 6 at 4:56 AM | marketbeat.com

6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know

May 5 at 9:16 PM | benzinga.com

Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts

May 5 at 8:00 PM | insidermonkey.com

Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview

May 5 at 4:15 PM | benzinga.com

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

May 5 at 6:27 AM | prnewswire.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Here's What Happened

May 5 at 3:33 AM | marketbeat.com

Analysts Just Made A Substantial Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Forecasts

May 4, 2025 | finance.yahoo.com

Allostery Investments LP Invests $753,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 4, 2025 | marketbeat.com

Ally Bridge Group NY LLC Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 4, 2025 | marketbeat.com

Voleon Capital Management LP Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 4, 2025 | marketbeat.com

Earnings call transcript: Tarsus Pharmaceuticals Q1 2025 sees robust sales growth

May 3, 2025 | investing.com

Tarsus Pharmaceuticals Reports 217% Increase in XDEMVY® Sales and Strengthens Financial Position with $135 Million Equity Offering

May 3, 2025 | nasdaq.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Price T Rowe Associates Inc. MD

May 3, 2025 | marketbeat.com

Tarsus Pharmaceuticals’ Earnings Call Highlights Robust Growth

May 2, 2025 | tipranks.com

Tarsus Pharmaceuticals anticipates 85,000-90,000 XDEMVY bottles dispensed in Q2 2025 amid expanded DTC campaign

May 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, KNSA, TARS, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$17.25 +1.02 (+6.28%)

Closing price 03:59 PM Eastern

Extended Trading

$17.55 +0.30 (+1.74%)

As of 08:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals NASDAQ:KNSA

$26.72 -0.05 (-0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$26.72 0.00 (0.00%)

As of 05:30 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Stoke Therapeutics NASDAQ:STOK

$9.09 +0.43 (+4.91%)

Closing price 03:59 PM Eastern

Extended Trading

$9.05 -0.04 (-0.39%)

As of 06:38 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Tarsus Pharmaceuticals NASDAQ:TARS

$47.14 -0.21 (-0.44%)

Closing price 03:59 PM Eastern

Extended Trading

$47.14 0.00 (0.00%)

As of 07:00 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time